Table 8:
Model Variable Inputs Used in the Base Case Analysis
| Model Parameters | Base Case Value | Range | Reference |
|---|---|---|---|
| Probability of severe adverse events resulting from Argus II implantation in the first year | 0.3333 | 0.2499–0.4166 | Humayun et al, 201228 |
| Annual probability of severe adverse events between years 1 and 3 | 0.0465 | 0.0349–0.0581 | Ho et al, 2015,24,28 and Humayun et al, 2012,28 plus calculation |
| Annual probability of severe adverse events between years 3 and 5 | 0.04257 | 0.0319–0.0532 | da Cruz et al, 201619 |
| Probability of patients achieving GVA in the first year after Argus II implantation | 0.4820 | 0.3615–0.6025 | Humayun et al, 201228 |
| Annual probability of patients moving from GVA to NGVA between years 1 and 3 | 0.1688 | 0.1266–0.2110 | Ho et al, 2015,24,28 and Humayun et al, 2012,28 plus calculation |
| Probability of Argus II explantation in year 1 | 0.0333 | 0.0249–0.0416 | Humayun et al, 201228 |
| Probability of Argus II explantation in year 2 | 0.0347 | — | da Cruz et al, 201619 |
| Probability of Argus II explantation in year 3 | 0.0351 | — | da Cruz et al, 201619 |
| Standardized mortality ratio, patients with retinitis pigmentosa vs. general population | 1.56 | 1.28–2.61 | Na et al, 201730 |
| Mortality from the Canadian life-table | Life-table | — | Statistics Canada31 |
| Discount rate | 1.5% | 0%–5% | CADTH26,27 |
Abbreviations: CADTH, Canadian Agency for Drugs and Technologies in Health; GVA, grating visual acuity; NGVA, no grating visual acuity.